ARWR Arrowhead Pharmaceuticals Inc

Price (delayed)

$81.14

Market cap

$8.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.84

Enterprise value

$8.18B

Sector: Healthcare
Industry: Biotechnology

Highlights

The quick ratio has soared by 191% YoY and by 8% from the previous quarter
The equity has soared by 89% YoY but it has contracted by 6% from the previous quarter
The gross profit is down by 48% YoY and by 29% QoQ
The company's revenue fell by 48% YoY and by 29% QoQ

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
102.38M
Market cap
$8.31B
Enterprise value
$8.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.97
Price to sales (P/S)
92.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
93.01
Earnings
Revenue
$87.99M
EBIT
-$93.74M
EBITDA
-$87.8M
Free cash flow
-$107.34M
Per share
EPS
-$0.84
Free cash flow per share
-$1.07
Book value per share
$4.51
Revenue per share
$0.87
TBVPS
$5.04
Balance sheet
Total assets
$522.5M
Total liabilities
$60.72M
Debt
$21.14M
Equity
$461.78M
Working capital
$281.69M
Liquidity
Debt to equity
0.05
Current ratio
7.92
Quick ratio
7.78
Net debt/EBITDA
1.39
Margins
EBITDA margin
-99.8%
Gross margin
100%
Net margin
-96.1%
Operating margin
-105.9%
Efficiency
Return on assets
-15.2%
Return on equity
-17.4%
Return on invested capital
-39.7%
Return on capital employed
-19.5%
Return on sales
-106.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-3.55%
1 week
-1.23%
1 month
-3.62%
1 year
81.89%
YTD
5.75%
QTD
5.75%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$87.99M
Gross profit
$87.99M
Operating income
-$93.16M
Net income
-$84.55M
Gross margin
100%
Net margin
-96.1%
The operating income has dropped by 179% since the previous quarter
The gross profit is down by 48% YoY and by 29% QoQ
The company's revenue fell by 48% YoY and by 29% QoQ

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
17.97
P/S
92.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
93.01
The price to book (P/B) is 157% higher than the 5-year quarterly average of 7.0 and 97% higher than the last 4 quarters average of 9.1
The equity has soared by 89% YoY but it has contracted by 6% from the previous quarter
The price to sales (P/S) is 159% more than the last 4 quarters average of 35.9 but 72% less than the 5-year quarterly average of 332.9
The company's revenue fell by 48% YoY and by 29% QoQ

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
The company's return on assets has shrunk by 176% YoY
The company's return on equity has shrunk by 154% YoY
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 117% YoY and by 82% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
The quick ratio has soared by 191% YoY and by 8% from the previous quarter
The company's current ratio has surged by 190% YoY and by 7% QoQ
Arrowhead Pharmaceuticals's debt is 95% lower than its equity
The equity has soared by 89% YoY but it has contracted by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.